A Phase 2 interventional study of Everolimus and Pasireotide LAR in Islet Cell Tumor, sponsored by Novartis Pharmaceuticals. Terminated at 47 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET.
A planned primary analysis was completed with data cut of 02-Apr-2014. The study did not meet its primary objective, which was based on progression-free survival (PFS) as per local radiology assessment and was prematurely terminated with the last patient last visit on 19-Feb-2015. However, it is important to note that the data did not reveal any new safety concerns. It was decided to stop the study and this decision was shared with the study sites on 31-Jul-2014.
113 studies on the registry are indexed under Adenoma, Islet Cell; 30 are open to participants now.
This study's enrollment of 160 is above the median of 38 across 76 interventional studies indexed under Adenoma, Islet Cell.
Browse Adenoma, Islet Cell studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
Drug: Everolimus · Drug: Pasireotide LAR
everolimus 10 mg once daily po alone
Drug: Everolimus
Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
Also known as: RAD001
Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
Also known as: SOM230 LAR
Progression-free Survival (PFS) Per Local Radiological Review
PFS per RECIST 1.0. (Response Evaluation Criteria in Solid Tumors). PFS was defined as the time from the date of randomization to the date of the first radiologically documented disease progression or death due to any cause.
Time frame: Once 80 PFS events had occurred aproximately after 24 months
Safety and Tolerability Profile of Everolimus Alone or in Combination With Pasireotide LAR
Consisted of monitoring and recording the rate, type, severity, and causal relationship of adverse events (AEs) and serious AEs (SAEs) to treatment. The safety analysis was based mainly on the frequency of AEs or SAEs and on the number of laboratory values that fell outside of pre-determined range.
Time frame: Once 80 PFS events had occurred
Objective Response Rate (ORR) as Per Radiology Review
Objective response was determined by the local radiologist according to the RECIST Version 1.0. ORR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR). This is also referred to as Overall response rate. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline.
Time frame: Once 80 PFS events had occurred
Duration of Response (DoR)
80 PFS are expected after approximately 24 months. Kaplan Meier was initially planned to be used to depict duration of response by treatment group and by stratum. Later based on the mode of action of everolimus and pasireotide and based on study experience, only a low number of objective responses per RECIST were expected. Therefore, protocol was amended to only list duration of response, and confirmed responses were flagged in the listing. Hence, statistical analyses were not planned and such data are not available for the following table.
Time frame: Once 80 PFS events had occurred
Overall Survival (OS) Using Kaplan Meier Method
Overall survival was defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival was to be censored at the date of last contact.
Time frame: Once 80 PFS events had occurred
PFS and the Predictive Probability of Success in Phase III
105 PFS events expected after approximately 36 months
Time frame: Once 105 PFS events had occurred occurred
Disease Control Rate (DCR) as Per Radiology Review
Disease control rate is the percentage of patients with a best overall response of CR or PR or stable disease (SD) determined by the local radiologist according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) Version 1.0. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease (PD). PD: Any progression ≤ 18 weeks after randomization (and not qualifying for CR, PR or stable disease SD.
Time frame: Once 80 PFS events had occurred
Summary of Pharmacokinetics (PK) for Everolimus for AUClast
Time frame: Cycle 2 Day 1
Summary of Pharmacokinetics (PK) for Everolimus for CL/F
Time frame: Cycle 2 Day 1
Summary of Pharmacokinetics (PK) for Everolimus for Cmax and Cmin
Time frame: Cycle 2 Day 1
Summary of Pharmacokinetics (PK) for Everolimus for Tmax
Time frame: Cycle 2 Day 1
Summary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg
Time frame: Cycle 1 Day 21, Cycle 2 Day 29
| Milestone | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Started | 79 | 81 |
| Completed | 78 | 81 |
| Not completed | 1 | 0 |
| Withdrew: Administrative problems | 1 | 0 |
PFS per RECIST 1.0. (Response Evaluation Criteria in Solid Tumors). PFS was defined as the time from the date of randomization to the date of the first radiologically documented disease progression or death due to any cause.
| months | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Progression-free Survival (PFS) Per Local Radiological Review | 16.82 (12.09 to 19.58) | 16.59 (11.07 to 19.48) |
Consisted of monitoring and recording the rate, type, severity, and causal relationship of adverse events (AEs) and serious AEs (SAEs) to treatment. The safety analysis was based mainly on the frequency of AEs or SAEs and on the number of laboratory values that fell outside of pre-determined range.
| Participants | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Deaths | 7 | 10 |
| Serious Adverse Events | 41 | 49 |
| Adverse Events | 78 | 81 |
Objective response was determined by the local radiologist according to the RECIST Version 1.0. ORR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR). This is also referred to as Overall response rate. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline.
| Percentage of participants | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Objective Response Rate (ORR) as Per Radiology Review | 20.3 (12.0 to 30.8) | 6.2 (2.0 to 13.8) |
80 PFS are expected after approximately 24 months. Kaplan Meier was initially planned to be used to depict duration of response by treatment group and by stratum. Later based on the mode of action of everolimus and pasireotide and based on study experience, only a low number of objective responses per RECIST were expected. Therefore, protocol was amended to only list duration of response, and confirmed responses were flagged in the listing. Hence, statistical analyses were not planned and such data are not available for the following table.
No measurements were reported for this outcome.
Overall survival was defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival was to be censored at the date of last contact.
| Percentage of participants | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| 6 months | 93.5 (85.0 to 97.2) | 93.7 (85.5 to 97.3) |
| 12 months | 85.5 (75.4 to 91.7) | 86.1 (76.2 to 92.0) |
| 18 months | 81.4 (70.6 to 88.5) | 75.5 (64.3 to 83.6) |
| 24 months | 77.0 (65.6 to 85.1) | 71.0 (59.3 to 79.9) |
105 PFS events expected after approximately 36 months
No measurements were reported for this outcome.
Disease control rate is the percentage of patients with a best overall response of CR or PR or stable disease (SD) determined by the local radiologist according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) Version 1.0. CR: Disappearance of all nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameter of all target lesions recorded at or after baseline. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease (PD). PD: Any progression ≤ 18 weeks after randomization (and not qualifying for CR, PR or stable disease SD.
| Percentage of participants | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Disease Control Rate (DCR) as Per Radiology Review | 77.2 (66.4 to 85.9) | 82.7 (72.7 to 90.2) |
| ng*hr/mL | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Summary of Pharmacokinetics (PK) for Everolimus for AUClast | 511 ± 91.8 | 378 ± 123 |
| L/hr | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Summary of Pharmacokinetics (PK) for Everolimus for CL/F | 20.0 ± 3.21 | 29.0 ± 9.51 |
| ng/mL | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Cmax | 58.7 ± 25.9 | 60.2 ± 30.6 |
| Cmin | 14.7 ± 4.81 | 7.67 ± 4.41 |
| hr | Paseriotide LAR + Everolimus | Everolimus |
|---|---|---|
| Summary of Pharmacokinetics (PK) for Everolimus for Tmax | 1.00 ± 4.81 | 0.500 ± 4.41 |
| ng/mL | Paseriotide LAR + Everolimus |
|---|---|
| Cycle 1 Day 21 (n:69) | 21.6 ± 13.1 |
| Cycle 2 Day 29 (n: 64) | 19.9 ± 12.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus LAR + Pasireotide | — | 41/78 (52.6%) | 77/78 (98.7%) |
| Everolimus | — | 49/81 (60.5%) | 80/81 (98.8%) |
| Event | Everolimus LAR + Pasireotide | Everolimus |
|---|---|---|
| PyrexiaGeneral disorders | 5/78 | 6/81 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/78 | 1/81 |
| AnaemiaBlood and lymphatic system disorders | 0/78 | 5/81 |
| Abdominal painGastrointestinal disorders | 1/78 | 5/81 |
| SepsisInfections and infestations | 2/78 | 4/81 |
| NauseaGastrointestinal disorders | 1/78 | 3/81 |
| VomitingGastrointestinal disorders | 2/78 | 3/81 |
| CholangitisHepatobiliary disorders | 2/78 | 3/81 |
| Renal failureRenal and urinary disorders | 1/78 | 3/81 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/78 | 3/81 |
| Event | Everolimus LAR + Pasireotide | Everolimus |
|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 56/78 | 23/81 |
| StomatitisGastrointestinal disorders | 46/78 | 51/81 |
| DiarrhoeaGastrointestinal disorders | 49/78 | 43/81 |
| Oedema peripheralGeneral disorders | 26/78 | 31/81 |
| Abdominal painGastrointestinal disorders | 22/78 | 29/81 |
| NauseaGastrointestinal disorders | 27/78 | 24/81 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/78 | 28/81 |
| FatigueGeneral disorders | 21/78 | 27/81 |
| HeadacheNervous system disorders | 17/78 | 26/81 |
| Weight decreasedInvestigations | 24/78 | 25/81 |
Full analysis set (FAS) was defined according to the intention to treat principle. The FAS consisted of all randomized patients. Following the intention to treat principle patients were analyzed according to the treatment (and stratum) they were assigned to at randomization.
| Age, Continuous(Years) | Paseriotide LAR + Everolimus | Everolimus | Total |
|---|---|---|---|
| Mean | 56.52 ± 11.978 | 58.22 ± 12.650 | 57.38 ± 12.314 |
| Gender(Participants) | Paseriotide LAR + Everolimus | Everolimus | Total |
|---|---|---|---|
| Female | 40 | 34 | 74 |
| Male | 39 | 47 | 86 |
The record gives a start of Jun 2011, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus